Clinical Trials Logo
  1. Home
  2. Non-hodgkin Lymphoma,B Cell
  3. NCT04094142

Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Non-hodgkin Lymphoma,B Cell Clinical Trial

Official title:
Phase II Trial of Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Clinical Trial Summary

NCCN guidelines for B cell lymphoma suggest that patients with relapsed/refractory aggressive NHL who are candidate for high-dose therapy should receive combination of cytotoxic chemotherapies as 2nd line treatment. However, proportion of patients who are adequately salvaged by second line chemotherapy and high-dose chemotherapy with stem cell rescue is unsatisfactory. Moreover, many fragile patients are unfit for salvage cytotoxic chemotherapy and/or high-dose chemotherapy. Hence, most of patients with relapsed/refractory aggressive B-cell NHL is ultimately candidate for less-cytotoxic drugs with targeted approach. This trial is phase II trial of acalabrutinib in combination with rituximab and lenalidomide for these patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04094142
Study type Interventional
Source Seoul National University Hospital
Contact
Status Completed
Phase Phase 2
Start date July 9, 2019
Completion date May 15, 2022
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05050461 - Immune Response After SARS-CoV-2 Vaccination in a Context of Non-Hodgkin Lymphoma N/A
Recruiting NCT06160362 - The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL) N/A
Recruiting NCT04435743 - Efficacy and Safety of Lenalidomide With or Without Rituximab and Other Drugs in B-cell Non-Hodgkin's Lymphomas
Recruiting NCT03720496 - Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell Therapy Phase 1
Recruiting NCT05518383 - B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 Phase 4
Recruiting NCT02081937 - CART-19 Immunotherapy in Mantle Cell Lymphoma Phase 1/Phase 2
Recruiting NCT06321289 - Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL Phase 1/Phase 2
Not yet recruiting NCT05909059 - CAR T-cell Therapy in Patients With Renal Dysfunction Phase 2
Recruiting NCT05631912 - TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL Phase 1/Phase 2
Not yet recruiting NCT06156774 - SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project
Recruiting NCT05143112 - Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Lymphoma Phase 1/Phase 2
Recruiting NCT04661020 - CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma Phase 2
Recruiting NCT03497533 - Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19 Phase 1/Phase 2
Recruiting NCT04532268 - A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL Early Phase 1
Terminated NCT03488251 - PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma Phase 2
Recruiting NCT05741359 - The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma Phase 1
Recruiting NCT04897477 - Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma Phase 1/Phase 2
Not yet recruiting NCT06346912 - CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL Early Phase 1